Time filter

Source Type

Ribeil J.-A.,French National Center for Scientific Research | Ribeil J.-A.,University of Paris Descartes | Ribeil J.-A.,Institute des Maladies Genetiques | Ribeil J.-A.,Laboratoire dExcellence des Globules Rouges GR ex | And 21 more authors.
The Scientific World Journal | Year: 2013

In humans, β-thalassemia dyserythropoiesis is characterized by expansion of early erythroid precursors and erythroid progenitors and then ineffective erythropoiesis. This ineffective erythropoiesis is defined as a suboptimal production of mature erythrocytes originating from a proliferating pool of immature erythroblasts. It is characterized by (1) accelerated erythroid differentiation, (2) maturation blockade at the polychromatophilic stage, and (3) death of erythroid precursors. Despite extensive knowledge of molecular defects causing β-thalassemia, less is known about the mechanisms responsible for ineffective erythropoiesis. In this paper, we will focus on the underlying mechanisms leading to premature death of thalassemic erythroid precursors in the bone marrow. © 2013 Jean-Antoine Ribeil et al.

Paubelle E.,University of Paris Descartes | Paubelle E.,French Institute of Health and Medical Research | Paubelle E.,Paris-Sorbonne University | Zylbersztejn F.,University of Paris Descartes | And 24 more authors.
PLoS ONE | Year: 2013

The prognosis of acute myeloid leukemia (AML) in elderly (≥65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies. Our group has shown that in vitro the iron chelator deferasirox (DFX) synergizes with vitamin D (VD) to promote monocyte differentiation in primary AML cells. Herein, we present results from a retrospective case-control study in which the association of DFX (1-2 g/d) and 25-hydroxycholecalciferol (100,000 IU/week) (DFX/VD) was proposed to patients following demethylating agents failure. Median survival of patients treated with DFX/VD combination (n = 17) was significantly increased in comparison with matched patients receiving best supportive care (BSC) alone (n = 13) (10.4 versus 4 months respectively). In addition, the only factor associated to an increased overall survival in DFX/VD-treated patients was serum VD levels. We conclude that DFX/VD treatment correlated with increased overall survival of AML patients in this retrospective cohort of elderly patients. © 2013 Paubelle et al.

Loading Laboratoire dExcellence des Globules Rouges GR ex collaborators
Loading Laboratoire dExcellence des Globules Rouges GR ex collaborators